ReviewContemporary clinical trials communications2021
Trial-level factors affecting accrual and completion of oncology clinical trials: A systematic review.
Review in Contemporary clinical trials communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- The Trial Enrollment Diversity Dashboard for Acute Leukemia Clinical Research: Intervention Development and Cohort Analysis.JCO oncology practice · 2025Trial
- Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas.International journal of radiation oncology, biology, physics · 2024Trial
- Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.The oncologist · 2024Trial
- What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020).BMJ open · 2022Trial
- AI-based augmentation of oncology clinical trials.Nature reviews. Clinical oncology · 2026Review
- Near-Real-Time Clinical Trial Accrual Dashboard in a National Cancer Institute-Designated Cancer Center: Mixed Methods Implementation Study.JMIR medical informatics · 2026Article
- Recent Trends in Clinical Trials for Pediatric Sarcoma in the United States: An Analysis of ClinicalTrials.gov.Children (Basel, Switzerland) · 2026Article
- Clinical research in private hospitals: a perspective.Journal of translational medicine · 2026Review
- A Multi-Model LLM Consensus Framework to Identify EHR-Predictable Eligibility Criteria in NSCLC Immunotherapy Trials.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
- The Outcome and Impact of Academic Cancer Clinical Trials with Participation from Canadian Sites (2015-2024).Cancers · 2025Article
- Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria.JCO global oncology · 2025Article
- Development and implementation of cancer clinical trial patient screening using an electronic medical record-integrated trial matching system.BMJ health & care informatics · 2025Article
- Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study.Journal of medical Internet research · 2025Article
- Barriers and facilitators to enrollment in pediatric clinical trials: an overview of systematic reviews.Systematic reviews · 2024Review
- A student-community partnership to enhance cancer research training.BMC medical education · 2024Article
- Article
- Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs.Targeted oncology · 2024Article
- Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Review
- Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.Journal of the advanced practitioner in oncology · 2024Article
- Patient Experience, Adverse Event Reporting, and Clinical Trial Design.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer is the second-leading cause of death in the United States. Clinical trials translate basic science discoveries into treatments needed by cancer patients. Inadequate accrual of trial participants is one of the most significant barriers to the completion of oncology clinical trials.
objectiveThe purpose of this study was to investigate trial-level factors that affect accrual and/or completion of oncology clinical trials, identify gaps in the literature, and indicate opportunities for future research.
designA systematic review of the literature on trial-level factors that affect accrual and/or completion of oncology clinical trials was performed. Searches in PubMed and Scopus identified 6582 studies. Based on eligibility criteria, 16 studies were selected for the review. Results were analyzed according to the following: a) background factors, b) disease-related, c) treatment-related, and d) trial design.
resultsBackground factors that were investigated in relation to oncology clinical trial accrual and/or completion included sponsor, number and location of participating institutions, competing trials, time of trial opening, and fast-track status. Disease-related factors included the annual incidence and type(s) of targeted cancer. Several types of treatment such as drugs, radiation and surgery were examined in the studies. Trial design factors included trial development time, eligibility criteria, randomization, sample size, trial phase, placebo use, and required protocol procedures and their timing.
conclusionWith low patient participation rates in oncology clinical trials that hold promise for future treatments, it is imperative that trial-level factors affecting accrual be identified and addressed to facilitate the completion of trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.